Articles tagged "Rejection"

2020 American Transplant Congress
Role of Cell Free DNA (Allosure) Testing in Recipients of Kidneys with Sub Optimal Donor Quality
Y. A. Qazi, W. Mon, M. Smogorzewski
USC, Los Angeles, CA
*Purpose: The purpose of this study was to evaluate the role of cell-free DNA testing ( Allosure, CareDx, Brisbane , CA) during graft dysfunction in…
2020 American Transplant Congress
Tissue Resident Memory T Cells in Mouse Renal Transplantation
K. Abou-Daya¹, D. Zhao¹, R. Tieu¹, R. Rammal², M. Oberbarnscheidt¹, F. Lakkis¹
¹Starzl Transplantation Institute, Pittsburgh, PA, ²American University of Beirut, Beirut, Lebanon
*Purpose: The newly identified tissue resident subset of memory T cells (TRM) provides immune surveillance in the tissue and first response against infections. They are…
2020 American Transplant Congress
Molecular Profiles of Injury in Heart Transplant Allograft: Relationship to Rejection, Ejection Fraction, and Survival
P. Halloran¹, J. Reeve², &. the INTERHEART Study Group³
¹University of Alberta, Edmonton, AB, Canada, ²Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ³., ., AB, Canada
*Purpose: In previous studies we used microarray analysis of gene expression to identify rejection in heart transplant endomyocardial biopsies, and found that this also revealed…
2020 American Transplant Congress
Donor Derived Cell Free DNA (dd-cfDNA) and Gene Expression Signatures of Antibody-Mediated Rejection (ABMR) May Improve Accuracy of ABMR Diagnosis (Dx)
H. Zhang¹, C. C. Nast², E. Huang³, N. Ammerman³, A. A. Vo³, S. C. Jordan³, M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, ³Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Dd-cfDNA has a clinically meaningful association with early Dx of ABMR. Here, we evaluated dd-cfDNA measured prior to for-cause biopsies (Bx), and also measured…
2020 American Transplant Congress
Analysis of Rejection, Rejection Therapy and Renal Function in the BEST Trial
H. Kuzaro¹, A. R. Shields², A. Wiseman³, S. Tremblay¹, A. Christianson¹, D. Kaufman⁴, J. Leone⁵, A. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Colorado, Denver, CO, ⁴U Wisconsin, Madison, WI, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷UIC, Chicago, IL
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal) compared two belatacept (BELA)-based early corticosteroid withdrawal (ESW) regimens and alemtuzumab (ALEM) or rabbit antithymocyte globulin (rATG)…
2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, J. Choi¹, S. C. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…
2020 American Transplant Congress
Glomerulitis in One-Hour Biopsy after ABO-Blood Type Incompatible Kidney Transplantation Sensitively Suggests Occurrence of Antibody-Mediated Rejection
D. Iwami, K. Hotta, N. Iwahara, N. Shinohara
Renal and Genitourinary Surgery, Hokkaido University, Graduate School of Medicine, Sapporo, Japan
*Purpose: Antibody-mediated rejection (ABMR) after ABO-blood type-incompatible kidney transplantation (ABOi-KTx) can affect transplant outcome even lead to allograft loss unless promptly diagnosed and adequately treated.…
2020 American Transplant Congress
Peripheral Blood T- and B-Cells as Predictors of Acute Rejection in Pancreas Transplant Recipients
P. Ventura Aguiar¹, J. Rovira², M. Ramirez-Bajo², E. Bañón-Maneus², N. Hierro², M. Garcia Criado³, M. Cuatrecasas⁴, J. Ferrer⁵, E. Esmatjes⁶, J. Campistol¹, F. Diekmann¹
¹Nephrology and Kidney Transplantation, Hospital Clinic Barcelona, Barcelona, Spain, ²Laboratori Experimental de Nefrologia i Trasplantament, Fundacio Clinic - IDIBAPS, Barcelona, Spain, ³Radiology Department, Hospital Clinic Barcelona, Barcelona, Spain, ⁴Pathology Department, Hospital Clinic Barcelona, Barcelona, Spain, ⁵HepatoBilioPancreatic Surgery Department, Hospital Clinic Barcelona, Barcelona, Spain, ⁶Endocrinology Department, Hospital Clinic Barcelona, Barcelona, Spain
*Purpose: Pancreas transplantation is associated with a high risk of acute rejection. The effect of peripheral blood mononuclear cells (PBMC) on acute rejection (AR) outcomes…
2020 American Transplant Congress
Risk Stratification in Antibody Incompatible Kidney Transplantation: Can Aggressive Rejection be Avoided?
S. Punjala¹, M. Ibrahim¹, N. Vallant¹, N. Kessaris¹, O. Shaw², N. Mamode¹
¹Department of Nephrology, Renal Transplant and Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ²Clinical Transplantation Laboratory, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
*Purpose: Our experience in antibody incompatible kidney transplantation, and anecdotal reports, suggest that a specific form of rejection, which we term Early Aggressive Antibody Mediated…
2020 American Transplant Congress
Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection – Molecular Rebound Phenomena Under IL-6 Blockade?
A. Borski¹, S. Haindl², M. Duerr³, K. Budde³, S. Schranz¹, F. A. Eskandary², K. Doberer², P. F. Halloran⁴, E. Chong⁵, B. Jilma¹, G. A. Böhmig², M. Wahrmann²
¹Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Medical University of Vienna, Vienna, Austria, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Vitaeris Inc., Vancouver, BC, Canada
*Purpose: Late antibody-mediated rejection (ABMR) is well established as a major cause of kidney allograft failure. Targeting interleukin-6 (IL-6), a pro-inflammatory cytokine involved in B…